Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Anika Therapeutics (ANIK)

34.64   -3.49 (-9.15%) 03-07 04:39
Open: 38.05 Pre. Close: 38.13
High: 38.05 Low: 33.73
Volume: 235,212 Market Cap: 492M
Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 38.096 - 38.334 38.334 - 38.502
Low: 33.216 - 33.487 33.487 - 33.677
Close: 34.279 - 34.682 34.682 - 34.966

Technical analysis

as of: 2021-03-05 5:04:58 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 43.91     One year: 46.70
Support: Support1: 33.73    Support2: 28.06
Resistance: Resistance1: 37.59    Resistance2: 39.98
Pivot: 36.89
Moving Average: MA(5): 37.68     MA(20): 37.18
MA(100): 38.32     MA(250): 35.75
MACD: MACD(12,26): -0.42     Signal(9): -0.51
Stochastic oscillator: %K(14,3): 50.01     %D(3): 62.21
RSI: RSI(14): 39.27
52-week: High: 47.48  Low: 22.01  Change(%): -7.7
Average Vol(K): 3-Month: 12402  10-Days: 16361

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
ANIK has closed above bottom band by 4.1%. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 05 Mar 2021
Anika Therapeutics Inc. (ANIK) Plunges 9.15% on March 05 - Equities.com

Fri, 05 Mar 2021
Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Reported, And Analysts Assigned A US$47.50 Price Target - Yahoo Finance

Thu, 04 Mar 2021
Anika Therapeutics Inc (ANIK) Q4 2020 Earnings Call Transcript - The Motley Fool

Thu, 04 Mar 2021
Anika Therapeutics (ANIK) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Thu, 04 Mar 2021
Anika Therapeutics EPS beats by $0.01, misses on revenue - Seeking Alpha

Thu, 04 Mar 2021
Anika Reports Fourth Quarter and Year-End 2020 Financial Results - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 14
Shares Float (M) 13
% Held by Insiders 1.60
% Held by Institutions 98.77
Shares Short (K) 1,490
Shares Short P. Month (K) 1,690

Stock Financials

EPS -0.300
EPS Est This Year 2.050
EPS Est Next Year 1.930
Book Value (p.s.) 20.020
Profit Margin -3.35
Operating Margin 8.13
Return on Assets (ttm) 1.8
Return on Equity (ttm) -1.5
Qtrly Rev. Growth 6.7
Gross Profit (p.s.) 6.042
Sales Per Share 8.975
EBITDA (p.s.) 1.538
Qtrly Earnings Growth
Operating Cash Flow (M) 24
Levered Free Cash Flow (M) 15

Stock Valuations

PE Ratio -115.47
PEG Ratio
Price to Book value 1.73
Price to Sales 3.86
Price to Cash Flow 20.95

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.